Clinical Trial Search

Primary: Percentage of Participants With Overall Confirmed Objective Disease Response — 36.8 percentage of participants

Primary: Percentage of Participants Surviving at Six Months of Treatment Without Evidence of Disease Progression. — 35.7; 27.3; 7.4; 35.7 Percentage of Participants

Primary: Any Unprotected Anal Intercourse (UAI) With Casual Partners — 2.0; 6.2 Number of episodes — p=< 0.05

Primary: Visual Acuity - Right Eye — 0.015; -0.044; -0.012 logMAR units

Primary: Condom Use During Vaginal Sex With Any Male Partner — 59.3; 39.6 Percent — p=<0.05

Primary: MET-weighted MVPA: Daily Minutes of Moderate-to-vigorous Physical Activity (MVPA) Weighted by Metabolic Equivalent of Task (MET) — 136.5; 136.9 Minutes of MET-weighted…

Primary: Percentage Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at 12 Months — -0.13; -0.62; 1.50; 2.65 Percentage change — p=<=0.001

Primary: Composite Criteria: Insulin Independence and Glycosylated Hemoglobin (HbA1c) Under 6.5% at One Year — 71 Percentage of patients

Primary: Proportion of Subjects Surviving at One Year — 0.405 proportion

Primary: The Weekly Mean Number of Standard Drinks Consumed Per Day at Baseline and Treatment Phase — -6.7 Standard Drinks — p=<0.0003

Primary: Pediatric Evaluation of Disability Inventory — 14.6; 6.4; 8.0; 7.9 Units on scale — p=0.02

Primary: Number of Participants With a Reduction in Total Tumor Volume of at Least 20%. — 0 Participants

Primary: Participants Whose Rebleeds Decreased From Baseline by ≥ 50% at 12 Months — 20; 1 participants — p=0.00000013

Primary: The Percent of Patients (Pts) With Objective Disease Response — 34 Percent of participants

Primary: Time to Vaso-occlusive Pain Crisis (VOC) Resolution — 61.83; 55.16 Hours — p== 0.8085